Resistell AG receives €2.5M EIC Accelerator grant and equity financing offer from EIC

Bacteria such as Pseudomonas aeruginosa are becoming resistant to the widely used antibiotic Ciprofloxacin (CIP). As resistance like this spreads the pioneering work of Resistell becomes more urgent. See how we’re leading the search for faster and more accurate diagnosis.

First case of super-resistant gonorrhea reported⚠️ The emergence of a strain of ‘super-gonorrhoea’, resistant to existing antibiotics, means that a global medical crisis is closer to becoming a reality. @Resistell are utilising the latest technology to create the speed and accuracy needed to fight back against that crisis.

SNSF NRP 72 Antimicrobial Resistance about Resistell.

Real world testing of Resistell methods is the next step in refining and making actual use of our innovations. Our device produces the resistance profile of a pathogen within a few hours instead of days.

On 02.03.2018 the Resistell team presented at Novel Antimicrobials and AMR Diagnostics conference in Berlin. Our MVP attracted a lot of attention!

We invite you to meet us in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (02.03.2018). We welcome you at our stand and invite to see our pitch.

Resistell on the 11th Berlin Conference on Life Sciences 💉 💉 Join us in Berlin on 02.03 at 16:00 at Fraunhofer-Forum Berlin SpreePalais!!! 😉